NLS Pharmaceutics AG Statistics
Share Statistics
NLS Pharmaceutics AG has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -73.77 and the forward PE ratio is null.
| PE Ratio | -73.77 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -101.65 |
| P/FCF Ratio | -92.72 |
| PEG Ratio | n/a |
Enterprise Valuation
NLS Pharmaceutics AG has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.23, with a Debt / Equity ratio of -0.18.
| Current Ratio | 0.23 |
| Quick Ratio | 0.23 |
| Debt / Equity | -0.18 |
| Total Debt / Capitalization | -22.69 |
| Cash Flow / Debt | -5.93 |
| Interest Coverage | -81.34 |
Financial Efficiency
Return on equity (ROE) is 1.38% and return on capital (ROIC) is 163.99%.
| Return on Equity (ROE) | 1.38% |
| Return on Assets (ROA) | -6.59% |
| Return on Capital (ROIC) | 163.99% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -0.52, so NLS Pharmaceutics AG's price volatility has been lower than the market average.
| Beta | -0.52 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 43.07 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, NLS Pharmaceutics AG had revenue of $0 and earned -$12.17M in profits. Earnings per share was $-0.32.
| Revenue | 0 |
| Gross Profit | -11.41K |
| Operating Income | -11.81M |
| Net Income | -12.17M |
| EBITDA | -11.80M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.32 |
Balance Sheet
The company has $897.68K in cash and $1.63M in debt, giving a net cash position of -$736.07K.
| Cash & Cash Equivalents | 897.68K |
| Total Debt | 1.63M |
| Net Cash | -736.07K |
| Retained Earnings | -70.37M |
| Total Assets | 1.19M |
| Working Capital | -6.53M |
Cash Flow
In the last 12 months, operating cash flow was -$9.68M and capital expenditures -$4, giving a free cash flow of -$9.68M.
| Operating Cash Flow | -9.68M |
| Capital Expenditures | -4 |
| Free Cash Flow | -9.68M |
| FCF Per Share | -0.25 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NLSPW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for NLSPW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -151.33 |
| Piotroski F-Score | 1 |